Carbapenemase-producing organism (CPO) colonisation at a district general hospital: universal screening may help reduce transmission.
Carbapenemase
Colonisation
Incidence
Screening
Surveillance
Journal
Infection prevention in practice
ISSN: 2590-0889
Titre abrégé: Infect Prev Pract
Pays: England
ID NLM: 101777928
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
28
02
2021
accepted:
23
07
2021
entrez:
14
10
2021
pubmed:
15
10
2021
medline:
15
10
2021
Statut:
epublish
Résumé
Assess the potential of hospital-wide routine screening by determining the prevalence and incidence of carbapenemase-producing organisms (CPOs) isolated from rectal screens at Barnet and Chase Farm Hospitals. 3,553 samples were collected between 01/12/2018 and 31/08/2019: from adult critical care wards (universal screening - admission, discharge and weekly), from medical wards with risk-factor based screening according to the prevailing Public Health England (PHE) carbapenemase-producing Enterobacteriaceae (CPE) screening guidelines, or on an ad hoc basis. Prevalence was defined as previously documented positive CPO colonisation, or new positive status, as a proportion of all eligible samples. Incidence was defined as all newly positive patients per 1,000 patient-days. Overall CPO prevalence was 2.1% (95% CI: 1.61-2.58%). Inpatient prevalence was significantly higher at 2.6% vs outpatient at 0.5% ( Surveillance remains a cornerstone in controlling CPO transmission. Our local incidence, lacking hospital-wide screening, significantly exceeded the reported UK average. Universal screening could help to uncover the true prevalence and incidence of CPO, thereby providing the necessary information to properly control transmission, reducing nosocomial outbreaks and ultimately reducing the overall cost to healthcare.
Identifiants
pubmed: 34647013
doi: 10.1016/j.infpip.2021.100164
pii: S2590-0889(21)00053-6
pmc: PMC8498735
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100164Informations de copyright
© 2021 The Authors.
Références
J Antimicrob Chemother. 2018 Jun 1;73(6):1452-1459
pubmed: 29438542
Clin Infect Dis. 2018 Apr 3;66(8):1290-1297
pubmed: 29165604
Eur J Clin Microbiol Infect Dis. 2017 Jun;36(6):1047-1055
pubmed: 28078557
J Hosp Infect. 2019 Apr;101(4):426-427
pubmed: 30826342
Infect Dis Clin North Am. 2016 Jun;30(2):313-322
pubmed: 27208761
J Antimicrob Chemother. 2017 Feb;72(2):596-603
pubmed: 27687074